Skip to main content
Tagrisso results encouraging as first-line EGFR lung cancer treatment

A late-stage study reported at the European Society for Medical Oncology found that AstraZeneca's Tagrisso, currently approved as a therapy for lung cancer patients with EGFR mutations who have received other treatments first, showed positive results as a first-line treatment compared with standard-of-care tyrosine kinase inhibitors. Risk of disease progression or death was 54% lower with Tagrisso, and serious side effects were lower as well.

Full Story: